The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines
Open accessAbstract
OBJECTIVE: To identify the number of drug-disease and drug-drug interactions for exemplar index conditions within National Institute of Health and Care Excellence (NICE) clinical guidelines. DESIGN: Systematic identification, quantification, and classification of potentially serious drug-disease and drug-drug interactions for drugs recommended by NICE clinical guidelines for type 2 diabetes, heart failure, and depression in relation to 11 other common conditions and drugs recommended by NICE guidelines for those conditions. SETTING: NICE clinical guidelines for type 2 diabetes, heart failure, and depression MAIN OUTCOME MEASURES: Potentially serious drug-disease and drug-drug interactions. RESULTS: Following recommendations for prescription in 12 national clinical guidelines would result in several potentially serious drug interactions. There were 32 potentially serious drug-disease interactions between drugs recommended in the guideline for type 2 diabetes and the 11 other conditions compared with six for drugs recommended in the guideline for depression and 10 for drugs recommended in the guideline for heart failure. Of these drug-disease interactions, 27 (84%) in the type 2 diabetes guideline and all of those in the two other guidelines were between the recommended drug and chronic kidney disease. More potentially serious drug-drug interactions were identified between drugs recommended by guidelines for each of the three index conditions and drugs recommended by the guidelines for the 11 other conditions: 133 drug-drug interactions for drugs recommended in the type 2 diabetes guideline, 89 for depression, and 111 for heart failure. Few of these drug-disease or drug-drug interactions were highlighted in the guidelines for the three index conditions. CONCLUSIONS: Drug-disease interactions were relatively uncommon with the exception of interactions when a patient also has chronic kidney disease. Guideline developers could consider a more systematic approach regarding the potential for drug-disease interactions, based on epidemiological knowledge of the comorbidities of people with the disease the guideline is focused on, and should particularly consider whether chronic kidney disease is common in the target population. In contrast, potentially serious drug-drug interactions between recommended drugs for different conditions were common. The extensive number of potentially serious interactions requires innovative interactive approaches to the production and dissemination of guidelines to allow clinicians and patients with multimorbidity to make informed decisions about drug selection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Barnett, K., Mercer, S. W., Norbury, M., Watt, G., Wyke, S., & Guthrie, B. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60240-2 · Cited by 6,972
Self-citationAdverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients
Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A. K., Walley, T. J., Farrar, K., Park, B. K., & Breckenridge, A. M. (2004) · BMJ · doi:10.1136/bmj.329.7456.15 · Cited by 3,230
Boyd, C. M., Darer, J., Boult, C., Fried, L. P., Boult, L., & Wu, A. W. (2005) · JAMA · doi:10.1001/jama.294.6.716 · Cited by 2,581
(1958) · Journal of the American Pharmaceutical Association (Scientific ed.) · doi:10.1002/jps.3030470133 · Cited by 2,489
Summary of product characteristics
(2013) · Pharmaceutical Medicine · doi:10.1093/med/9780199609147.003.0027 · Cited by 1,905
Boyer, E. W., & Shannon, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041867 · Cited by 1,821
Andrews, J. C., Schünemann, H. J., Oxman, A. D., Pottie, K., Meerpohl, J. J., Coello, P. A., Rind, D., Montori, V. M., Brito, J. P., Norris, S., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.02.003 · Cited by 1,315
Van Spall, H. G. C., Toren, A., Kiss, A., & Fowler, R. A. (2007) · JAMA · doi:10.1001/jama.297.11.1233 · Cited by 1,055
National Institute for Health and Care Excellence.
Cowie, M. (2015) · PubMed · Cited by 645
Adapting clinical guidelines to take account of multimorbidity
Guthrie, B., Payne, K., Alderson, P., McMurdo, M. E. T., & Mercer, S. W. (2012) · BMJ · doi:10.1136/bmj.e6341 · Cited by 530
Self-citationHughes, L. D., McMurdo, M. E. T., & Guthrie, B. (2013) · Age and Ageing · doi:10.1093/ageing/afs100 · Cited by 506
Self-citationKesselheim, A. S. (2008) · JAMA · doi:10.1001/jama.2008.758 · Cited by 431
Adverse drug events in the outpatient setting: an 11‐year national analysis
Bourgeois, F. T., Shannon, M. W., Valim, C., & Mandl, K. D. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1984 · Cited by 333
Increasing polypharmacy - an individual-based study of the Swedish population 2005-2008
Hovstadius, B., Hovstadius, K., Åstrand, B., & Petersson, G. (2010) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-10-16 · Cited by 290
Enhancing Physicians’ Use of Clinical Guidelines
Pronovost, P. J. (2013) · JAMA · doi:10.1001/jama.2013.281334 · Cited by 288
Schedlbauer, A., Prasad, V., Mulvaney, C., Phansalkar, S., Stanton, W., Bates, D. W., & Avery, A. J. (2009) · Journal of the American Medical Informatics Association · doi:10.1197/jamia.m2910 · Cited by 262
Multimorbidity, polypharmacy, referrals, and adverse drug events: are we doing things well?
Calderón-Larrañaga, A., Poblador-Plou, B., González-Rubio, F., Gimeno-Feliu, L. A., Abad-Díez, J. M., & Prados-Torres, A. (2012) · British Journal of General Practice · doi:10.3399/bjgp12x659295 · Cited by 236
Guthrie, B., McCowan, C., Davey, P., Simpson, C. R., Dreischulte, T., & Barnett, K. (2011) · BMJ · doi:10.1136/bmj.d3514 · Cited by 219
Self-citationZhang, M., Holman, C. D. J., Price, S. D., Sanfilippo, F. M., Preen, D. B., & Bulsara, M. K. (2009) · BMJ · doi:10.1136/bmj.a2752 · Cited by 208
Uhlig, K., Leff, B., Kent, D., Dy, S., Brunnhuber, K., Burgers, J. S., Greenfield, S., Guyatt, G., High, K., Leipzig, R., et al. (2014) · Journal of General Internal Medicine · doi:10.1007/s11606-013-2659-y · Cited by 158
Creating Clinical Practice Guidelines We Can Trust, Use, and Share
Vandvik, P. O., Brandt, L., Alonso‐Coello, P., Treweek, S. P., Akl, E. A., Kristiansen, A., Heen, A. F., Agoritsas, T., Montori, V. M., & Guyatt, G. H. (2013) · CHEST Journal · doi:10.1378/chest.13-0746 · Cited by 151
Self-citationTHIERS, B. H. (2008) · Yearbook of Dermatology and Dermatologic Surgery · doi:10.1016/s0093-3619(08)70887-6 · Cited by 109
Ruscitto, A., Smith, B. H., & Guthrie, B. (2014) · European Journal of Pain · doi:10.1002/ejp.520 · Cited by 105
Self-citationLorgunpai, S. J., Grammas, M., Lee, D. S. H., McAvay, G., Charpentier, P. A., & Tinetti, M. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089447 · Cited by 103
Understanding adverse drug reactions in older adults through drug–drug interactions
Marengoni, A., Pasina, L., Concoreggi, C., Martini, G., Brognoli, F., Nobili, A., Onder, G., & Bettoni, D. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.10.001 · Cited by 91
Evidence-Based Medicine and the Hard Problem of Multimorbidity
Boyd, C. M., & Kent, D. M. (2014) · Journal of General Internal Medicine · doi:10.1007/s11606-013-2658-z · Cited by 69
Unhelpful information about adverse drug reactions
Tan, K., Petrie, K. J., Faasse, K., Bolland, M. J., & Grey, A. B. (2014) · BMJ · doi:10.1136/bmj.g5019 · Cited by 62
Reid, R. J., & Wagner, E. H. (2014) · Journal of General Internal Medicine · doi:10.1007/s11606-014-2827-8 · Cited by 11
Cited by
Smith, S. M., Wallace, E., O'Dowd, T., & Fortin, M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006560.pub3 · Cited by 883
An update on the clinical consequences of polypharmacy in older adults: a narrative review
Wastesson, J. W., Morin, L., Tan, E. C. K., & Johnell, K. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1546841 · Cited by 617
Challenges of managing people with multimorbidity in today’s healthcare systems
Moffat, K., & Mercer, S. W. (2015) · BMC Family Practice · doi:10.1186/s12875-015-0344-4 · Cited by 349
Self-citationToo much medicine in older people? Deprescribing through shared decision making
Jansen, J., Naganathan, V., Carter, S. M., McLachlan, A. J., Nickel, B., Irwig, L., Bonner, C., Doust, J., Colvin, J., Heaney, A., et al. (2016) · BMJ · doi:10.1136/bmj.i2893 · Cited by 303
Tan, Y. Y., Papez, V., Chang, W. H., Mueller, S. H., Denaxas, S., & Lai, A. G. (2022) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(22)00186-6 · Cited by 283
Metadata
- Authors
- Dumbreck, S., Flynn, A., Nairn, M., Wilson, M., Treweek, S., Mercer, S. W., Alderson, P., Thompson, A., Payne, K., & Guthrie, B.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2015-03-11
- Volume
- 350
- Issue
- mar11 2
- Pages
- h949-h949
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W2171466942
- Cited by
- 339
- References
- 28
- FWCI
- 16.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.